INTRODUCTION
The selection of an appropriate labeling method for a protein or peptide requires careful consideration of the fate of the molecule after its interaction with the biological milieu. For radio-iodinated proteins and peptides, circumventing the action of the deiodinases normally involved in thyroid hormone metabolism is an important general concern. This led to the development of reagents such as N-succinimidyl 3-[*I]iodobenzoate (SIB), which yield proteins that do not undergo appreciable deiodination in vivo based on their Tyr-dissimilar structure 1, 2 . However, when a labeled protein or peptide undergoes cellular internalization after binding to a cell surface receptor or antigen, then, depending on its intercellular routing, considerable loss of label from the targeted cell can occur [3] [4] [5] . Although this discussion is focused on mAbs for simplicity of presentation, this problem can affect other proteins and peptides also. For example, loss of label after cellular internalization of conventionally radio-iodinated epidermal growth factor receptor (EGFR) was first demonstrated 30 years ago by Carpenter and Cohen 6 .
The internalization process can subject mAbs to extensive catabolism, primarily reflecting the action of proteases present in the lysosomal compartment of the targeted cells. Labeling of mAbs with radiometals is generally easy, and for mAbs labeled with radiometals such as 90 Y and 177 Lu, low-molecular-weight labeled catabolites egress from a tumor to only a small degree 7 . Compared with radio-iodinated mAbs, this results in higher accumulation of radioactivity in the tumor; however, high renal uptake and low tumor/normal tissue ratios are often drawbacks. When mAbs that undergo internalization are labeled with radio-iodine by direct electrophilic substitution on their Tyr residues, in general, the radioactivity is rapidly lost from the tumor cells, primarily in the form of monoiodotyrosine 8 . No significant advantage with respect to tumor retention of radioactivity was seen even when such mAbs were labeled with SIB, confirming that a process other than deiodination was responsible for loss of label after mAb internalization 9 .
Newer radio-iodination methods are needed that will result in higher retention of radioactivity in tumor cells after the internalization of labeled mAbs. A number of such 'residualizing labels' have been developed. With these methods, the portion of the molecule bearing the label is inert to lysosomal degradation and becomes trapped inside the cell after mAb proteolysis. The first set of reagents for this purpose (e.g., tyramine-cellobiose (TCB) and inulin-tyramine) contained a non-metabolizable carbohydrate moiety in their structure [10] [11] [12] [13] [14] . Use of these methods to label internalizing mAbs generally resulted in improved tumor retention of radioactivity compared with their directly iodinated counterparts. However, there are a number of disadvantages associated with this labeling approach, including low protein-labeling yields, low immunoreactivity of the labeled mAbs, protein cross-linking and (as a result of the latter) higher liver uptake 10, [14] [15] [16] . A more successful method for radio-iodination of internalizing mAbs involves the use of oligopeptides composed of D-amino acids 3, 17 . The unnatural D-amino acids are not substrates for proteases; peptides consisting of more than three D-amino acids are expected to be trapped within the cells because passive transport of peptides of that size is poor. A variation of this tactic that has been described previously is to attach very hydrophilic molecules such as DTPA (diethylenetriamine pentaacetic) to the D-amino acid peptide 4, 18 . This is based on the rationale that when mAbs are labeled with radiometals using chelating agents such as DTPA, the radioactivity is retained in the cells in the form of radiometal-DTPA-Lys.
Our laboratory has been investigating an alternative strategy for labeling internalizing mAbs that is based on the hypothesis that exocytosis of labeled catabolites across cells and lysosomal membranes can be minimized if they are charged species. As the pH of the lysosomal compartment is approximately 5, species containing basic functions are expected to remain positively charged within the lysosomes. To test the feasibility of this approach, studies were performed using N-succinimidyl 5-[*I]iodopyridine-3-carboxylate ([*I]SIPC), a reagent containing a positively charged pyridine ring, to label an internalizing mAb, L8A4, reactive with EGFRvIII, a mutant form of the EGFR 9 . Up to 65% higher intracellular retention of radioactivity was observed in vitro for L8A4 labeled using [*I]SIPC compared with L8A4 mAb labeled directly or using [*I]SIB; however, this advantage was transient. On the other hand, excellent tumor/tissue ratios were seen with mAb labeled using [*I]SIPC compared with other methods, primarily because of lower normal organ radio-iodine levels.
The reagent described here, N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate ([*I]SGMIB), is an extension of the cationic labeled catabolite concept. Guanidine has a pK a of approximately 13 and is therefore expected to remain exclusively in the protonated form within the lysosome. We have exploited this property to develop a conjugation labeling agent useful in the radio-iodination of internalizing mAbs 19 . [*I]SGMIB was derived simply by attaching a guanidinomethyl function to SIB (Fig. 1 ). An unlabeled standard of SGMIB (4), its Boc-protected derivative (Boc-SGMIB, 2) and the tin precursor N-succinimidyl 4-[N 1 , N 2 -bis(tert-butyloxycarbonyl)guanidinomethyl]-3-(trimethylstannyl)benzoate (Boc-SGMTB, 3) were obtained from 3-iodo-4-methylbenzoic acid (1) in multiple steps 19 . An SGMIB analog labeled with an a-particleemitting heavy halogen, 211 (20 1C) . The labeled protein is purified using gravity gel filtration chromatography. Typical yields for the conjugation are 60-65% for protein concentrations of 3 mg ml À1 or higher.
With this protocol, it may not be feasible to synthesize [*I]SGMIB at radioactivity levels that are needed for clinical radio-immunotherapy. To accomplish this, the procedure will need to be modified so that it can be performed using a remotecontrolled automated synthesizer.
Experimental design
This protocol describes the synthesis of radio-iodinated SGMIB from a protected tin precursor (Boc-SGMTB). Neither Boc-SGMTB nor the corresponding iodo derivative Boc-SGMIB is commercially available, but they can be synthesized following literature protocols 19 . For the most part, 0.2 mg Boc-SGMTB is used for a radio-iodination reaction. Methods for synthesis and small quantities of these compounds are available on request.
MATERIALS

REAGENTS
. Boc-SGMIB, 2 (synthesize according to the literature protocol 19 ) . Boc-SGMTB, 3 (synthesize according to the literature protocol 19 ) ! CAUTION As an active ester, SGMTB can undergo slow hydrolysis; however, when it is stored under argon at À20 1C, no detectable decomposition has been observed for months, if not years.
. . Normal 2| Using a Pipetman with a micro tip attached, dispense the required amount of radio-iodine in 0.1 N NaOH into a 1 ml Reacti vial. ! CAUTION Radio-iodine is volatile (particularly in the oxidized form) and needs to be handled in a well-ventilated charcoalfiltered hood with adequate lead shielding. If you are not familiar with dealing with radioactivity, it is recommended that you consult your institutional Radiation Safety Office to determine appropriate protective measures and radioactivity monitoring devices. If the volume of radio-iodine solution is more than 3 ml, it should be concentrated to a volume of 3 ml or less using a gentle stream of argon. m CRITICAL STEP It is best to use fresh batches of radio-iodine. With time, byproducts of higher oxidation states such as iodate and periodate may be formed, which can compromise the efficiency of the radio-iodination reaction. Although radiochemical yields are generally considerably higher, it is recommended that you conservatively assume a yield of 50% to calculate the initial amount of radio-iodine added to the reaction vessel.
3| Add 3 ml solution of HOAc in chloroform (3%, vol/vol). If radio-iodine volumes higher than 3 ml must be used, adjust the concentration of the HOAc solution so that the volume will still be 3 ml. For example, if 6 ml radio-iodine is used, then use 3 ml 6% (vol/vol) HOAc.
4| Add 5 ml TBHP solution prepared in Step 1.
5| Add a solution of Boc-SGMTB in chloroform (15 ml 20 mM, 0.2 mg).
6| Add a triangular stir bar, cap the vial and stir the mixture at room temperature (20 1C) for 30 min.
7| Withdraw the entire reaction mixture into a 250 ml HPLC syringe. Rinse the reaction vial with 50 ml chloroform and withdraw the rinse into the same HPLC syringe. Inject the syringe contents onto a normal-phase HPLC column eluted isocratically with 25:75 ethyl acetate/hexanes containing 0.2% (vol/vol) HOAc at a flow rate of 1 ml min À1 . m CRITICAL STEP Approximately 5% of the radioactivity frequently sticks to the reaction vial. Additional chloroform (50 ml) rinses can extract some of this radioactivity; however, larger volumes of chloroform in the injectant will compromise chromatographic resolution. ethyl acetate, transfer the rinse to the 1/2-dram vial and evaporate the ethyl acetate. Repeat the rinsetransfer-evaporation process one time.
10| Add 0.1 ml TFA to the radioactivity in the 1/2-dram vial, gently vortex the vial and allow the de-protection reaction to proceed at room temperature (20 1C) for 15 min.
11| Evaporate the TFA with a stream of argon. To ensure complete removal of TFA, add 3 Â 0.1 ml ethyl acetate and evaporate it each time.
TIMING
Step 1: 10 min; 
